Tempus AI, Inc. (TEM) Form 8-K — Nov 2, 2026
Tempus AI reported Q3 2026 revenue of $411.5 million, up 23% year over year, with oncology volume growth accelerating to 32% and Data & Applications revenue up 33%. Net loss narrowed sharply to $14.9 million from $80.0 million, while Adjusted EBITDA jumped to $25.6 million from $1.5 million. The company raised full-year 2026 revenue guidance to $1.60-$1.605 billion (~25% growth) and reaffirmed ~$65 million Adjusted EBITDA. It ended the quarter with $854.4 million in cash and marketable securities.
Key figures
- Revenue
- 411537000
- Guidance
- FY2026 revenue raised to $1.60-$1.605 billion (~25% growth); Adjusted EBITDA ~$65 million
- Revenue Yoy
- 23%
- Cash Position
- 854400000
- Mrd tests q3
- ~12,000, up 300%
- Non gaap eps
- 0.07
- Bms deal value
- $137.5 million over five years
- Gross profit q3
- 266701000
- Adjusted ebitda q3
- 25572000
- Non gaap net income q3
- 13359000
- Oncology volume growth
- 32%
- Data apps revenue growth
- 33%
- Adjusted ebitda prior year
- 1476000
- Bms pathos alzheimers deal
- $55 million over five years
- Ytd data licensing bookings
- >$550 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.